QTTBQ32 Bio Inc.
$11.71
$0.93
(7.36%)
Reported EarningsMay 5
Mkt Cap$214.33M
Vol209,651.00
Fundamentals
Mkt Cap
$214.33M
Volume
-
52W High
$13.19
52W Low
$1.35
PE Ratio
4.75
Avg. Volume
1.41M
EPS (Annual)
$2.42
Rev/Employee
$2,239,041.67
Earnings
May 05
These Stocks Are Dominating the Power Hour into the Close
Today’s trading session saw aggressive momentum rotate back into speculative growth, biotech, AI infrastructure, and emerging technology names as traders hunted for high-volatility opportunities heading into the closing bell and after-hours session. Several low-float biotech and technology stocks experienced sharp increases in volume following clinical updates, financing announcements, analyst attention, and broader retail speculation. $NTHI, $QBTT, $ASTI, $MNTS, $APPS, $SNGX, $AMSS
24-7 Market News
Q32 Bio Announces $55 Million Private Placement Financing
Q32 Bio Announces $55 Million Private Placement Financing Q32 Bio Announces $55 Million Private Placement Financing PR Newswire WALTHAM, Mass., May 27, 2026 WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company...
PR Newswire
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 145.7% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
This Q32 Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Analysts change outlook on top names. Check out ratings page for upgrades, downgrades, and initiations.read more...
Benzinga
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade
The consensus price target hints at a 163.4% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Q32 Bio's (QTTB) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed a 'buy' rating and set a $13.00 price objective on shares of Q32 Bio in a research report on Tuesday...
MarketBeat
Q32 Bio (NASDAQ:QTTB) Announces Earnings Results, Beats Estimates By $0.14 EPS
Q32 Bio (NASDAQ:QTTB - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.14...
MarketBeat
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., May 5, 2026 -- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial...
PR Newswire
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
Zacks
<
1
2
...
>